Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-34. **(Cancelled)**

35. **(Currently Amended)** A method for identifying a compound that modulates production of a Th2-associated cytokine in a cell, comprising

providing an indicator composition comprising (i) a maf family protein ~~comprising an amino terminal transactivation domain and a carboxy terminal basic leucine zipper region~~ which binds to a MARE regulatory sequence of a Th2 associated cytokine gene~~;~~ and (ii) a target DNA comprising a MARE regulatory sequence of a Th2-associated cytokine gene to which said maf family protein binds, wherein said indicator composition is an indicator cell or an acellular preparation;

contacting the indicator composition with each member of a library of test compounds;

selecting from the library of test compounds a compound of interest that modulates binding of said maf family protein to said target DNA; and

determining the effect of the compound of interest on the production of a Th2-associated cytokine in a cell to thereby identify a compound that modulates production of the Th2 cytokine.

36. **(Previously Presented)** The method of claim 35, wherein the maf family protein is c-Maf.

37. **(Cancelled)**

38. **(Previously Presented)** The method of claim 35, wherein the Th2-associated cytokine gene is an interleukin-4 gene.

39. **(Previously Presented)** The method of claim 35, wherein the effect of the compound of interest on Th2-associated cytokine production is determined by determining the effect of the compound on development of T helper type 1 (Th1) or T helper type (Th2) cells.

40. **(Currently Amended)** The method of claim 35, wherein the maf family protein is ~~selected from the group consisting of:~~ v-maf~~, Nrl and p18~~.

41. **(Cancelled)**

42. **(Previously Presented)** The method of claim 35, wherein the target DNA comprises the regulatory sequence of an interleukin-4 gene.

43. **(Previously Presented)** The method of claim 35, wherein the indicator composition is an indicator cell.

44. **(Previously Presented)** The method of claim 43, wherein the indicator cell is a lymphoid cell.

45. **(Previously Presented)** The method of claim 44, wherein the lymphoid cell is a Th2 cell.

46. **(Previously Presented)** The method of claim 44, wherein the lymphoid cell is a Th1 cell.

47. **(Previously Presented)** The method of claim 44, wherein the lymphoid cell is a B cell.

48. **(Previously Presented)** The method of claim 43, wherein the indicator cell is a non-lymphoid mammalian cell.

49. **(Previously Presented)** The method of claim 43, wherein the indicator cell is a yeast cell.

50-55. **(Cancelled)**

56. **(Previously Presented)** The method of claim 44, wherein lymphoid cell is a helper precursor (Thp) cell.

57. **(New)** The method of claim 35, wherein the indicator composition is an acellular preparation.

58. **(New)** The method of claim 35, wherein the maf family protein is c-maf or v-maf and the Th2-associated cytokine gene is an IL-4 gene or an IL-10 gene.

59. **(New)** The method of claim 35, wherein the Th2-associated cytokine gene is an interleukin-10 gene.

60. **(New)** The method of claim 35, wherein the production of IL-4 is modulated.

61. **(New)** The method of claim 35, wherein the production of IL-10 is modulated.

62. **(New)** The method of claim 35, wherein the maf family protein is recombinantly expressed in a cell.

63. **(New)** The method of claim 35, wherein the cell does not naturally express the maf family protein.

64. **(New)** The method of claim 35, wherein the regulatory sequence comprises about 3 kb of the upstream regulatory sequences of the IL-4 gene.

65. **(New)** The method of claim 35, wherein the regulatory sequence comprises from about nucleotide -157 to about residue +58 relative to the start site of transcription of +1 of the IL-4 promoter.

66. **(New)** The method of claim 35, wherein Th2-associated cytokine production is assessed by detecting cytokine mRNA.

67. **(New)** The method of claim 35, wherein Th2-associated cytokine production is assessed by detecting the cytokine protein.